Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin

Toxicology

Volumn 264, Issue 1-2, 2009, Pages 52-60

  Škarydová, Lucie ^a   Skarka, Adam ^a   Novotná, Romana ^a   Živná, Lucie ^a   Martin, Hans Jörg ^b   Wsól, Vladimír ^a   Maser, Edmund ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Carbonyl reduction; Enzyme kinetics; Microsomes; Oracin; Purification

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CARBONYL REDUCTASE; ORACIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CONTROLLED STUDY; DRUG INACTIVATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME PURIFICATION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN FUNCTION; STEREOSPECIFICITY;

ALCOHOL OXIDOREDUCTASES; ANTINEOPLASTIC AGENTS; CELL MEMBRANE; CHROMATOGRAPHY, AGAROSE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ETHANOLAMINES; HUMANS; ISOQUINOLINES; KINETICS; MICROSOMES, LIVER; SOLUBILITY; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 69449091261     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.07.013     Document Type: Article

References (36)

1. Anonymous, 2001. Protein Purification Handbook 18-1132-29, Amersham Biosciences.
2. Belyaeva O.V., Korkina O.V., Stetsenko A.V., Kim T., Nelson P.S., and Kedishvili N.Y. Biochemical properties of purified human retinol dehydrogenase 12 (RDH12): catalytic efficiency toward retinoids and C9 aldehydes and effects of cellular retinol-binding protein type I (CRBPI) and cellular retinaldehyde-binding protein (CRALBP) on the oxidation and reduction of retinoids. Biochemistry 44 18 (2005) 7035-7047
3. Bhairi S.M. A Guide to the Properties and Uses of Detergents in Biological Systems (1997), Calbiochem-Novabiochem Corporation
4. Breyer-Pfaff U., and Nill K. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J. Pharm. Pharmacol. 56 12 (2004) 1601-1606
5. Chevallet M., Luche S., Diemer H., Strub J.M., Van D.A., and Rabilloud T. Sweet silver: a formaldehyde-free silver staining using aldoses as developing agents, with enhanced compatibility with mass spectrometry. Proteomics 8 23-24 (2008) 4853-4861
6. Gersl V., Mazurova Y., Bajgar J., Melka M., Hrdina R., and Palicka V. Lack of cardiotoxicity of a new antineoplastic agent, a synthetic derivative of indenoisochinoline: comparison with daunorubicin in rabbits. Arch. Toxicol. 70 10 (1996) 645-651
7. Hoffmann F., and Maser E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab. Rev. 39 1 (2007) 87-144
8. Jez J.M., Flynn T.G., and Penning T.M. A new nomenclature for the aldo-keto reductase superfamily. Biochem. Pharmacol. 54 6 (1997) 639-647
9. Jez J.M., and Penning T.M. The aldo-keto reductase (AKR) superfamily: an update. Chem. Biol. Interact. 130-132 1-3 (2001) 499-525
10. Kallberg Y., Oppermann U., Jornvall H., and Persson B. Short-chain dehydrogenase/reductase (SDR) relationships: a large family with eight clusters common to human, animal, and plant genomes. Protein Sci. 11 3 (2002) 636-641
11. Kasus-Jacobi A., Ou J., Bashmakov Y.K., Shelton J.M., Richardson J.A., Goldstein J.L., and Brown M.S. Characterization of mouse short-chain aldehyde reductase (SCALD), an enzyme regulated by sterol regulatory element-binding proteins. J. Biol. Chem. 278 34 (2003) 32380-32389
12. Liden M., and Eriksson U. Understanding retinol metabolism: structure and function of retinol dehydrogenases. J. Biol. Chem. 281 19 (2006) 13001-13004
13. Lukacik P., Kavanagh K.L., and Oppermann U. Structure and function of human 17beta-hydroxysteroid dehydrogenases. Mol. Cell Endocrinol. 248 1-2 (2006) 61-71
14. Marijanovic Z., Laubner D., Moller G., Gege C., Husen B., Adamski J., and Breitling R. Closing the gap: identification of human 3-ketosteroid reductase, the last unknown enzyme of mammalian cholesterol biosynthesis. Mol. Endocrinol. 17 9 (2003) 1715-1725
15. Martin H.J., Breyer-Pfaff U., Wsol V., Venz S., Block S., and Maser E. Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos. 34 3 (2006) 464-470
16. Maser E. Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. The pluripotency of several hydroxysteroid dehydrogenases. Biochem. Pharmacol. 49 4 (1995) 421-440
17. Maser E., and Bannenberg G. The purification of 11 beta-hydroxysteroid dehydrogenase from mouse liver microsomes. J. Steroid Biochem. Mol. Biol. 48 2-3 (1994) 257-263
18. Maser E., Volker B., and Friebertshauser J. 11 Beta-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry 41 7 (2002) 2459-2465
19. Matsunaga T., Shintani S., and Hara A. Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab. Pharmacokinet. 21 1 (2006) 1-18
20. Melka, M., 1993. Oracin-preclinical summary report of the research institute for pharmacy and biochemistry. Prague. Czech Republic. Ref Type: Generic.
21. Miko M., Poturnajova M., and Soucek R. Cytotoxicity and mode of action of the potential cytostatic drug oracin. Neoplasma 49 3 (2002) 167-171
22. Novotna R., Wsol V., Xiong G., and Maser E. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol. Lett. 181 1 (2008) 1-6
23. Oppermann U.C., Filling C., and Jornvall H. Forms and functions of human SDR enzymes. Chem. Biol. Interact. 130-132 1-3 (2001) 699-705
24. Persson B., Kallberg Y., Bray J.E., Bruford E., Dellaporta S.L., Favia A.D., Duarte R.G., Jornvall H., Kavanagh K.L., Kedishvili N., Kisiela M., Maser E., Mindnich R., Orchard S., Penning T.M., Thornton J.M., Adamski J., and Oppermann U. The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. Chem. Biol. Interact. 178 1-3 (2009) 94-98
25. Rosemond M.J., and Walsh J.S. Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab. Rev. 36 2 (2004) 335-361
26. Scopes R.K. Protein purification. Principle and practice (1994), Springer-Verlag, New York
27. Seddon A.M., Curnow P., and Booth P.J. Membrane proteins, lipids and detergents: not just a soap opera. Biochim. Biophys. Acta 1666 1-2 (2004) 105-117
28. Szotakova B., Wsol V., Trejtnar F., Skalova L., and Kvasnickova E. Studies on the metabolism of the potencial cytostatic drug oracin. Species differences. Exp. Toxicol. Pathol. 48 Suppl. II (1) (1996) 377-380
29. Wallin E., and Von-Heijne G. Genome-wide analysis of integral membrane proteins from eubacterial, archaean, and eukaryotic organisms. Protein Sci. 7 4 (1998) 1029-1038
30. Wsol V., Kvasnickova E., Szotakova B., and Hais I.M. High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracine. J. Chromatogr. B: Biomed. Appl. 681 1 (1996) 169-175
31. Wsol V., Skalova L., Szotakova B., Trejtnar F., and Kvasnickova E. Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo. Chirality 11 5-6 (1999) 505-509
32. Wsol V., Szotakova B., Kvasnickova E., and Fell A.F. High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison. J. Chromatogr. A 797 1-2 (1998) 197-201
33. Wsol V., Szotakova B., Martin H.J., and Maser E. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man. Toxicology 238 2-3 (2007) 111-118
34. Wsol V., Szotakova B., Skalova L., Cepkova H., and Kvasnickova E. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin. Enantiomer 5 3-4 (2000) 263-270
35. Wsol V., Szotakova B., Skalova L., and Maser E. The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11beta-hydroxysteroid dehydrogenase type 1. Toxicology 197 3 (2004) 253-261
36. Wu X., Lukacik P., Kavanagh K.L., and Oppermann U. SDR-type human hydroxysteroid dehydrogenases involved in steroid hormone activation. Mol. Cell Endocrinol. 265-266 (2007) 71-76